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                                          INTRODUCTION
The  tuberculosis  epidemic  is  expanding  and  currently  a  third  of  the  world's 
population  is  infected,  the  majority  residing  in  the  developing  world.[1] The 
epidemiology of IBD is also changing, though far less dramatically, with more cases 
from low and  middle  income  countries  being  reported.  There  exists  a  multifaceted 
relationship between intestinal  tuberculosis  (ITB) and Crohn's  disease  (CD),  as  they 
share common pathogenic and clinical characteristics and were thought to be one in the 
same disease. 
The interface between these two diseases is particularly relevant in the developing 
world where tuberculosis complicates both the diagnosis and management of CD. Eighty 
per  cent  of  all  new cases in 2004 occurred in  Africa,  South-East  Asia  and Western 
Pacific  regions[2] and  several  studies  have  shown  an  increasing  incidence  of  extra-
pulmonary TB.[3,4]  
Recently drug resistant tuberculosis has been reported from 17 countries including 
the USA.[5] Mortality in this untreatable form of TB is almost 100%.[6] In patients with 
active pulmonary tuberculosis concurrent ITB can occur in up to 46% of patients if the 
gastrointestinal  tract  is  examined.[7] Autopsy studies have also shown that  ITB often 
goes clinically undetected.[8]
Once  considered  rare  in  the  developing  world,  the  epidemiology  of  IBD  is 
changing and the incidence of both CD and ulcerative colitis (UC) is increasing in the 
Asian Pacific region, India, Eastern Europe and South Africa.[9-11] This is heralded by an 
increase in the incidence of UC followed by CD 15-20 years later.[12]
Making a diagnosis of Inflammatory Bowel Disease (IBD) in developed countries 
is facilitated by a limited differential diagnosis and unrestricted access to endoscopy and 
abdominal  imaging.  Moreover,  a  range  of  therapeutic  options,  including  costly 
biological therapies are available, well-developed healthcare infrastructure is in place 
and patients have ready access to information about their disease. In contrast IBD in the 
developing world is overshadowed by enteric infections and awareness of the condition, 
by both patient and clinician, is often limited. 
In  resource  poor  environments  access  to  technology,  such  as  endoscopy,  is 
reduced making the diagnosis of IBD difficult.  In those patients with an established 
diagnosis  of  IBD treatment  is  complicated  by  a  high  burden of  infectious  diseases, 
poorly  developed  healthcare  infrastructure  and  barriers  to  accessing  information. 
Furthermore, funding for IBD research in these environments is limited by competing 
healthcare needs.

AIMS OF THE STUDY
To  identify  the  distinctive  characteristics  of  ileocecal 
and  colonic  tuberculosis  (TB)  and  Crohn’s  disease  (CD)  at 
colonoscopy and 
1) To correlate the colonoscopic findings with histology
REVIEW OF LITERATURE
Crohn's  disease  (CD)  and  Tuberculosis  (TB)  are  both  chronic  granulomatous 
conditions which affect the gastrointestinal tract in a similar manner.  Mycobacterium 
tuberculosis is  the causative  organism in ITB whereas  the  etiology of  CD is  multi-
factorial and includes genetic, immunological, environmental and microbial factors. 
Tuberculosis, HIV and Crohn's Disease:
Intestinal TB and HIV co-infection varies from 0% in studies from Korea[37] and 
to 13% in an Indian study.[63] Although HIV is intimately linked to TB the HIV infected 
patient  develops  disseminated  TB  which  manifests  in  the  abdomen  as  ascites, 
lymphadenopathy and hepato-splenic disease, and is often smear negative. Confirming a 
diagnosis of abdominal TB in this clinical setting is difficult; however, the use of an 
expanded TB case definition and monitoring objective responses to anti-TB treatment 
has been used successfully as a diagnostic alternative in resource poor environments. In 
contrast  ITB with a Crohn's-like phenotype is usually seen in the immunocompetent 
patient with a robust immune response and 'contained' infection. The diagnosis of CD in 
an HIV infected patient should therefore only be made after very careful consideration. 
Conversely, established IBD patients in our environment are at risk of HIV infection 
commensurate with local prevalence patterns.
Immunopathogenesis:
Crohn's disease and TB are both chronic granulomatous conditions which affect 
the  gastrointestinal  tract  in  a  similar  manner.  It  is  not  surprising  given  striking 
morphological  similarities  that  they  share  many  common  immune  pathways  of 
pathogenesis,  nor that corticosteroids have been used effectively in both disorders to 
control deleterious inflammatory reactions.
 Both  the  diseases  trigger  potent  adaptive  TH1 cytokine  responses  which  result  in 
granuloma formation and are characterized by robust production of interferon-gamma 
(IFN-γ), IL-12 and IL-23.[13] 
In  contrast  to  the forceful  adaptive immune responses  seen,  both CD and TB 
appear  to  be associated with impaired innate  immunity.[14,15] Only 5-10% of patients 
infected with M. tuberculosis develop active tuberculosis. Furthermore, as with CD the 
protean  manifestations  of  TB  suggests  that  individual  variation  in  host-bacterial 
interactions may contribute to disease phenotype and that host genetics may play a role 
in dictating the efficacy of innate immune responses.
Nucleotide-binding  oligomerization  domain-2  (NOD2)  and  Toll-like  receptors 
(TLRs) may play a role in the early, inductive stages of both diseases. NOD2 single 
nucleotide polymorphisms (SNPs) confer susceptibility to CD in certain populations.[16] 
The role of Mycobacterium avium paratuberculosis (MAP) in the causation of Crohn’s 
disease has been debated with the possible explanation evoking the concept of molecular 
mimicry,  with  antibodies  directed  against  mycobacterial  antigen  cross  reacting  with 
intestinal components. [17] Both TB and CD are characterized by enormous heterogeneity 
and it may be, as has been shown in CD, that polymorphisms predict disease phenotype.
There  has  been  a  longstanding  debate  on  the  role  of  Mycobacterium  avium 
paratuberculosis (MAP) in CD, which remains unresolved. It has long been recognized 
that CD does not exist in germ-free environments and that luminal bacteria are required 
for  the  development  of  inflammation  in  animal  models  of  IBD.  The  recognition  of 
NOD2 gene mutations in enhancing susceptibility to CD has placed emphasis on the role 
of luminal microflora in this disorder. It is, however, overly simplistic to assume a true 
infectious causality of CD given the success of anti- tumour necrosis factor-α (TNF-α) 
therapies,  which  should  markedly  worsen  the  course  of  an  active  mycobacterial 
infection. As such if MAP plays a role,  it  is likely to be a little more esoteric. One 
possible explanation evokes the concept of molecular mimicry, with antibodies directed 
against mycobacterial antigen cross reacting with intestinal components.
Clinical presentation:
In  developed  nations,  TB  is  a  disease  of  immigrants,  the  indigent  or 
institutionalized or occurs in the immunosuppressed. In areas of high-TB prevalence, the 
disease is of the young or middle-aged with no distinguishing demographics. Intuitively 
the duration of symptoms would seem a distinguishing feature, but both diseases have an 
insidious onset which may go undiagnosed for many years. Furthermore, ITB has been 
identified  in  patients  undergoing  colonoscopy  who  were  either  well  or  had  trivial 
symptoms.
Both conditions are characterized by anorexia, loss of weight,  abdominal pain, 
altered bowel habits, rectal bleeding or the presence of an abdominal mass.[18,19] More 
acute presentations with intestinal perforation or obstruction, or intra-abdominal abscess 
can  also  occur.[20] Rarely  ITB may  present  with  malabsorption  and a  protein  losing 
enteropathy.[21] The site of involvement is also similar with a predilection for the ileo-
caecal region but both can involve the gastrointestinal tract from the mouth to anus. 
Fever is seen in both CD and ITB, but a high-swinging fever (>38.5 °C) favours ITB in 
the absence of any intra-abdominal abscess.[22]
Smoking is  an environmental  factor  associated with CD. Similarly  there  is  an 
association between smoking and tuberculosis infection in high-incidence areas. This 
may  be  explained  by  the  effect  of  cigarette  smoke  on  pulmonary  macrophage  or 
dendritic cell function.[23] However, there is no evidence showing a direct relationship 
between smoking and ITB.
Despite  their  morphological  and  immunopathogenic  similarities,  the  natural 
history of these two conditions is divergent. TB is associated with significant morbidity 
and  mortality[24] but  can  be  cured  with  a  6-month  course  of  anti-tuberculous 
chemotherapy. By contrast, CD is a chronic condition that tends to progress with time 
and  may  require  lifelong  therapy  to  maintain  disease  remission  in  the  majority  of 
patients.
In areas of high-TB prevalence, empiric treatment for TB with careful clinical 
review  is  often  resorted  to  when  diagnostic  uncertainty  exists.  This  approach  is 
problematic as it may delay treatment for CD or make it difficult to confirm or refute a 
diagnosis of ITB at a later stage. Furthermore, severe adverse drug reactions to anti-
tuberculous  chemotherapy  can  complicate  management  with  empiric  therapy. 
Conversely  treatment  for  CD may be disastrous  if  a  diagnosis  of  intestinal  TB was 
missed.
Clinical differentiation:
Despite  their  morphological  and  immunopathogenic  similarities,  the  natural 
history of these two conditions is divergent. ITB is associated with significant morbidity 
and  mortality,  but  can  be  cured  with  a  6-month  course  of  anti-tuberculous 
chemotherapy. By contrast, CD is a chronic condition that tends to progress with time 
and  may  require  lifelong  therapy  to  maintain  disease  remission  in  the  majority  of 
patients. 
Differentiating CD from ITB is difficult and although diagnostic criteria for both 
diseases exist they are not mutually exclusive.[24, 25] Both diseases have similar clinical, 
radiological  and endoscopic  features  and current  methods of  confirming a  diagnosis 
have limitations. In areas of high-TB prevalence, empiric treatment for TB with careful 
clinical review is often resorted to when diagnostic uncertainty exists.[26] 
This approach is problematic as it may delay treatment for CD or make it difficult 
to confirm or refute a diagnosis of ITB at a later stage. Furthermore, severe adverse drug 
reactions to anti-tuberculous chemotherapy can complicate management with empiric 
therapy. Conversely treatment for CD may be disastrous if a diagnosis of intestinal TB 
was missed.
This approach is problematic as it may delay treatment for CD or make it difficult 
to confirm or refute a diagnosis of ITB at a later stage. Furthermore, severe adverse drug 
reactions to anti-tuberculous chemotherapy can complicate management with empiric 
therapy. Conversely treatment for CD may be disastrous if a diagnosis of intestinal TB 
was missed.
Smoking is  an environmental  factor  associated with CD. Similarly  there is  an 
association between smoking and tuberculosis infection in high-incidence areas. This 
may  be  explained  by  the  effect  of  cigarette  smoke  on  pulmonary  macrophage  or 
dendritic  cell  function.  However,  there  is  no  evidence  showing a  direct  relationship 
between smoking and ITB.
Similar  to  TB,  a  variety  of  extra-intestinal  manifestations  of  CD  have  been 
described, including immunologically mediated reactive polyarthritis (Poncet's disease), 
erythema nodosum, erythema induratum, uveitis, and thrombo-embolic manifestations.
[27]  Fistulization is one of the clinical hallmarks of CD. However, entero-enteric, entero-
cutaneous and peri-anal fistulas are all well described in intestinal TB.[28]  Both Crohn's 
disease and ITB are associated with anaemia, leukocytosis, thrombocytosis, a low serum 
albumin and raised inflammatory markers and routine blood tests play no role in the 
differentiation of CD from ITB. 
Extra-pulmonary TB is often associated with a normal chest radiograph[29] Very 
rarely  Crohn's  may  involve  the  lung with  features  similar  to  PTB such as  a  milary 
pattern with granulomatous inflammation on transbronchial biopsy.[30] Thus, a normal 
chest x-ray does not exclude the diagnosis of intestinal TB and rarely CD may involve 
the lung.
The use of tuberculin skin testing (TST) as a diagnostic tool in patients with ileo-
colonic inflammation has limitations. Cross reactivity with BCG, a high prevalence of 
environmental  mycobacteria  and  widespread  latent  M.  tuberculosis infection  makes 
interpretation of a positive TST difficult. Anergy in HIV, primary TB and disseminated 
TB further limits the diagnostic utility of this test. Anergy has also been demonstrated in 
untreated CD patients.[31]
Colonoscopy:
Colonoscopy with intubation of  the terminal  ileum combined with endoscopic 
mucosal biopsy is required in the evaluation of any patient with suspected CD or ITB. 
The  majority  of  ITB  cases  will  involve  the  ileo-caecum  with  varying  degrees  of 
contiguous  colon  and  small  bowel  involvement.  In  approximately  20%  of  cases, 
segmental colonic involvement occurs in the absence of ileo-caecal involvement[32,33] and 
lesions in greater than two colonic sites, so-called skip lesions, may occur in up to 44% 
of patients.[34] Approximately 5% will present with a pancolitis picture indistinguishable 
from UC.[32,33,35] Isolated small intestinal or upper gastrointestinal tract disease is also 
well  described.[36] With  the  advent  of  endoscopy  the  type  of  lesion  rather  than  the 
distribution  has  become  important  in  differentiating  CD  from  ITB  (Table  1). 
Morphologically, circumferential,  transverse ulcers are more common in ITB (Fig 1) 
and linear, longitudinal ulcers are commonly seen in CD (Fig 2).
Lee  and  colleagues  in  the  first  systematic  prospective  analysis  evaluated 
endoscopic findings in 44 patients with ITB and 44 patients with CD. A scoring system 
comprising  four  endoscopic  features  of  CD  (anorectal  lesions,  longitudinal  ulcers, 
apthous ulcers, cobblestone appearance) vs. four endoscopic features of ITB (transverse 
ulcers,  pseudopolyps,  involvement  of  fewer than four  segments  and a  patulous ileo-
caecal valve) was used. With this method, a positive predictive value for CD of 94.9% 
and 88.9% for ITB was achieved.[37]
Table 1. Endoscopic Features of ITB and Crohn's Disease
Intestinal TB Crohn's disease
Circumferential Ulcers Longitudinal Ulcers
Surrounding  mucosa 
inflamed/nodular
Surrounding mucosa normal
Apthous ulcers uncommon Apthous ulcers common
Hyperaemic  nodules-isolated  or  in 
clusters
Cobblestoning
Pseudopolyps Multiple skip lesions
Hypertrophic mucosa Anorectal lesions
Strictures Strictures
Destruction of ICV and/or caecum Preservation of ICV
Histopathology:
Differentiating  ITB  from  CD  in  endemic  areas poses  a  major  challenge  to 
pathologists as both conditions are characterized by granulomatous inflammation with 
overlapping histologic features. Many early comparisons between these conditions were 
based on resection specimens,  in which the large sample size and availability of all 
layers of the bowel wall facilitated identification of pathognomonic lesions. However, 
many  of  these  features  are  non-specific  and  even  in  resection  specimens  it  can  be 
difficult to tell ITB and CD apart. 
In  ITB,  the  classical  and  pathognomonic  features  of  caseating  granulomatous 
inflammation and acid fast bacilli are present in <30% of cases, with a < 20% yield of 
positive TB culture often delaying the diagnosis.[38] Retrospective studies from South 
India [39, 40] and South Africa[41] have identified a number of features that appear helpful 
in distinguishing CD from ITB in colonoscopic biopsies (Table 2). 
The  histopathological  findings  frequently  seen  in  ITB  are  confluent 
granulomas, multiple granulomas in a given biopsy site, large granuloma size (Fig 3), 
bands  of  epithelioid  histiocytes  lining  ulcers,  submucosal  granulomas  and 
disproportionate submucosal inflammation,  apart from caseous necrosis and acid fast 
bacilli.[39-41] Features seen far more frequently in CD include single granulomas (Fig 4), 
as the only foci of granulomatous inflammation and architectural distortion distant from 
granulomatous inflammation.[39]
Table 2. Prevalence of Selected Histological Parameters in Patients with Intestinal 
Tuberculosis (ITB) and Crohn's Disease (CD): A Comparison of Three Studies [39- 
41]
 
Pulimood et al. 
(1999)  South 
India
Pulimood  et  al. 
(2005)  South 
India
Kirsch  et  al. 
(2006)  South 
Africa
ITB
(n=20)
CD
(n=20)
ITB
(n=33)
CD
(n=31)
ITB
(n=18)
CD
(n=25)
Caseous necrosis 40 0 36 0 22 0
Confluent 
granulomas
60 0 42 3 50 0
≥5 
granulomas/biopsy 
site
40 0 45 0 44 24
≥10 
granulomas/biopsy 
site
-- -- -- -- 33 0
Large granulomas Diameter  >  200 
µm
Diameter  >  400 
µm
Area > 0.05 mm2
90 5 51 0 67 8
Submucosal 
granulomas
45 5 39 6 44 12
Ulcers  lined  by 
bands  of 
epithelioid 
histiocytes
45 5 61 0 61 8
Disproportionate 
submucosal 
inflammation
65 5 -- -- 67 10
Architectural 
distortion  distant 
to  granulomatous 
inflammation
-- -- 0 62 -- --
On the other hand, studies from Western China did not find histology useful 
in distinguishing ITB and CD, but only assessed a few parameters including ulceration, 
lymphoid  aggregates,  chronic  inflammation,  confluent  granulomas  and  caseating 
granulomas.[37] The importance of taking multiple biopsies in cases of suspected ITB has 
been emphasized and significantly increases the diagnostic yield.[39] Biopsies should be 
taken  from  all  segments  of  the  bowel  including  both  endoscopically  normal  and 
abnormal  areas.[39] In  particular,  ulcerated  areas  should  be  thoroughly  sampled 
(including  multiple  biopsies  from both  the  base  and  the  edge  of  the  ulcer)  as  the 
diagnostic yield in ITB is highest in these lesions.[38]
Several studies suggest a role for PCR for mycobacterial DNA in the differential 
diagnosis  of  ITB and CD.[34,38] Four  retrospective studies  on formalin-fixed,  paraffin 
embedded colonoscopic biopsy specimens reported positive results in 22% (13/60), 45% 
(18/40), 64% (25/39), 75% (27/36) of ITB patients.
Radiology:
Barium studies allow visualization of the mucosal surface and luminal diameter 
and are valuable in demonstrating the inflammatory and cicatrising lesions found in both 
ITB and CD. Earlier work focussed on the pattern of ileo-caecal involvement as a means 
of diagnosing ITB (Fig 5). Examples of these include the Fleischner sign (a thickened 
patulous ICV combined with a narrowed terminal  ileum) and Stierlin's  sign (a rapid 
emptying of contrast through a gaping ileo-ceacal valve into a shrunken or 'amputated' 
caecum)[42]. 
A long segment of terminal ileal involvement, with skip lesions and preservation 
of  the  valve  and  caecum  was  considered  typical  of  CD  (Fig  6).  However,  these 
radiological signs are non-specific for either ITB or CD and a variety of other lesions 
such as  ulcers,  strictures,  fistulas,  fold  thickening,  mucosal  nodules  and bowel  loop 
separation have been described in both conditions.[43] 
With contrast enhanced CT scanning and MRI, and abdominal ultrasound bowel 
wall changes, mesenteric attachments, lymph nodes and other abdominal organs can be 
assessed and this may be useful in differentiating CD from ITB. When ITB occurs with 
concurrent TB of the peritoneum, mesentry and abdominal lymph nodes cross sectional 
imaging is often diagnostic in the high-prevalence environment. (Table 3). 
However, in isolated ileo-caecal TB cross sectional imaging is not diagnostic. ITB 
findings in this region include asymmetric caecal wall thickening,[44] an inflammatory 
mass  centred  around  the  caecum  and  enveloping  the  terminal  ileum  and  small 
homogenous pericaecal lymph nodes.[45] Features of CD include symmetrical bowel wall 
thickening,  fibrofatty  proliferation  of  the  mesentry  known as  'creeping  fat',  regional 
mesenteric nodes measuring 3-8 mm and enlarged mesenteric vascular bundles in the 
involved mesentry known as the comb sign.[46, 47] Extra-intestinal features of CD such as 
fatty liver, gallstones, primary sclerosing cholangitis and sacro-ileitis may also be seen 
on CT scan and MRI.[46, 48] 
Radiological imaging of the abdomen is invaluable in determining the extent of 
intestinal  disease  in  both  CD and ITB.  The presence  of  extra-luminal  features  may 
favour either ITB or CD. Functional MRI with improved luminal contrast techniques 
and CT enteroclysis allow better fistula definition and distinction between bowel wall 
fibrosis and inflammation;[49] however, the diagnostic capabilities of these new imaging 
modalities in environments with high rates for TB is unknown. At present conventional 
radiology in the majority of cases is not diagnostic.
Table 3. Radiological Features of ITB with Abdominal Involvement
Abdominal nodes
   12-50 mm
   Mesenteric, peri-pancreatic, periportal, pericaval, upper para-aortic
   Central areas of low attenuation
   Peripheral rim enhancement
   Node calcification
Ascites
   Free
   Fibrin stranding
   Loculated
Mesentry
   Thickening
   Nodularity
   Abscesses
   'Caked' omentum
Portal vein thrombosis
Hepato-splenic lesions
   Tuberculoma
   Diffuse micro-abscesses
Bowel wall thickening
Laparoscopy:
No systematic  laparoscopic  study  comparing  ITB to  CD has  been  conducted. 
Laparoscopy has been used as a diagnostic test in CD and the presence of creeping fat is 
associated with transmural inflammation.[50] However, mesenteric fat wrapping has also 
been  described  in  patients  undergoing  laparotomy  for  tuberculosis  in  India.[21,  26] 
Laparoscopy can be used for the diagnosis of peritoneal tuberculosis but its role in ITB 
is less clear.[51]
Management of Crohn's Patients in Regions with High Rates for Tuberculosis:
Managing CD with steroids, immunomodulatory therapy and biologicals in TB 
endemic  regions  presents  unique  challenges.  International  guidelines  have  evolved 
largely from research in populations with low TB prevalence and may not be appropriate 
in this environment. Therapies targeting TNF-α are associated with a higher incidence of 
TB than expected, and with extra-pulmonary and disseminated infection. This appears to 
be a class effect not unique to Infliximab. As such it is widely recommended that all 
patients be screened for active and latent TB before initiating any anti-TNF-α treatment.
[52] However, protocols for screening may not be adequate in endemic areas and a high 
index of suspicion is paramount. A detailed history of past infection, BCG vaccination, 
duration and adequacy of past treatment, recent contacts and suggestive symptoms must 
be ascertained. Furthermore, in this setting a chest radiograph is mandatory. If indicative 
every attempt must be made to exclude active infection, including sputum analysis and 
bronchoscopy as appropriate.
Far less clear is the most appropriate way in which to screen the asymptomatic 
patient  (with  a  normal  chest  radiograph)  for  latent  TB,  particularly  in  areas  with 
extensive  BCG  vaccination.  Tuberculin  Skin  Test  (TST)  has  several  limitations; 
interpretation is subject to observer bias, requires a second visit to read the results and 
sensitivity  can  be  reduced  in  immunocompromised  individuals.[53] Particularly 
controversial in the setting of endemic tuberculosis is what cut-off constitutes a positive 
TST as the test  is  hampered by cross-reactivity  of PPD antigens also present  in the 
Mycobacterium  bovis strain  used  for  BCG  vaccination  and  in  non-tuberculous 
mycobacteria  (NTM).  As  such  there  is  a  possibility  of  false-positive  testing,  which 
appears to diminish 15-years-postvaccination.[54] 
The traditional cut-off used in populations with widespread BCG vaccination is 10 
mm;  increasing  this  to  15  mm appears  to  improve  specificity  in  immunocompetent 
individuals, but at the expense of test sensitivity. [54] However, patients with CD have a 
very high incidence of anergy to TST and in keeping with international guidelines most 
considered  appropriate  for  anti-TNF-α  therapy  will  be  receiving  concurrent 
immunosuppressive medication or corticosteroids. [52] 
In  general,  a  negative  TST  does  not  exclude  latent  TB  in  patients  with  CD 
receiving  immunosuppressive  therapy.  However,  a  positive  TST  would  aid  in  the 
decision to implement TB prophylaxis, particularly if BCG vaccination was more than 
15 years previously.
It would be prudent to err on the side of caution and use a cut-off of >5 mm to 
recommend  TB  prophylaxis  in  immunosuppressed  patients  with  CD  living  in  TB 
endemic areas. This, however, remains to be validated.
In an attempt to circumvent the problems of TST, newer IFN-γ based assays have 
been  developed  to  evaluate  latent  TB.  These  tests  use  antigens  specific  to  M. 
